XML 36 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Discontinued Operations (Tables)
 9 Months Ended
Sep. 30, 2012
Balance Sheet [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The summary of the assets and liabilities related to Regenerative Medicine-China discontinued operations as of December 31, 2011 was as follows (in thousands):
 
December 31, 2011
Assets:
 

Cash and cash equivalents
$
103.3

Prepaid expenses and other current assets
284.4

Property, plant and equipment, net
1,256.8

Other Assets
149.0

 
$
1,793.5

Liabilities:
 
Accounts payable
$
177.8

Accrued liabilities
31.0

 
$
208.8
Balance Sheet [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The summary of the assets and liabilities related to Pharmaceutical Manufacturing - China discontinued operations as of September 30, 2012 and December 31, 2011, respectively, were as follows (in thousands):
 
September 30, 2012
 
December 31, 2011
Cash and cash equivalents
$
10,789.5

 
$
8,707.0

Restricted cash
2,892.4

 
—

Accounts receivable, net
7,105.3

 
5,525.7

Inventory
15,141.9

 
16,505.7

Deferred income taxes
344.2

 
463.7

Prepaid expenses and other current assets
750.9

 
777.5

Property, plant and equipment, net
37,327.3

 
36,490.4

Land use rights, net
3,021.5

 
4,872.4

Goodwill
—

 
8,495.7

Intangible assets, net
—

 
21,846.4

Other assets
2,821.1

 
2,459.9

Total assets
$
80,194.1

 
$
106,144.4

 
 
 
 
Accounts payable
$
8,730.5

 
$
7,950.3

Accrued liabilities
2,874.7

 
1,705.8

Bank loans
17,369.0

 
15,712.0

Notes payable
6,541.3

 
—

Income tax payable
2,142.3

 
621.6

Deferred income taxes
5,902.4

 
6,177.4

Unearned revenue
1,544.1

 
1,315.4

Amount due related parties
8,519.2

 
20,862.7

Total Liabilities
$
53,623.5

 
$
54,345.2
Income Statement [Member] | Regenerative Medicine - China segment [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):

Cash
$
195.1

Prepaid expenses and other current assets
14.9

Property, plant and equipment, net
1,023.7

Other Assets
330.5

Accounts payable
(177.1
)
Accrued liabilities
(79.2
)
Accumulated comprehensive income
(169.9
)
Loss on exit of segment
$
1,138.0

The operating results of the Regenerative Medicine – China business for the three and nine months ended September 30, 2012 and 2011, which are included in discontinued operations, were as follows (in thousands):
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2012
 
2011
 
2012
 
2011
Revenue
$
—

 
$
98.8

 
$
52.3

 
$
148.9

Cost of revenues
—

 
(31.3
)
 
(30.6
)
 
(49.4
)
Research and development
—

 
93.6

 
(103.3
)
 
(64.5
)
Selling, general, and administrative
—

 
(782.3
)
 
(497.3
)
 
(1,572.3
)
Other income (expense)
—

 
1.4

 
(6.8
)
 
(11.3
)
Loss on exit of segment
—

 
—

 
(1,138.0
)
 
—

Loss from discontinued operations
$
—

 
$
(619.8
)
 
$
(1,723.7
)
 
$
(1,548.6
)
Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member]
  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]
The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months ended September 30, 2012 and 2011, including the estimated asset impairments based on the definitive agreement purchase price, were as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2012
 
2011
 
2012
 
2011
Revenue
$
20,036.4

 
$
15,513.0

 
$
57,254.7

 
$
49,806.0

Cost of revenues
(11,551.5
)
 
(11,905.1
)
 
(37,131.5
)
 
(36,207.1
)
Research and development
(611.8
)
 
(782.5
)
 
(2,231.5
)
 
(1,885.3
)
Selling, general, and administrative
(3,514.7
)
 
(2,107.4
)
 
(9,714.8
)
 
(8,233.5
)
Other expense
(0.9
)
 
(583.2
)
 
(1,008.3
)
 
(949.3
)
Provision for income taxes
(1,029.9
)
 
(26.2
)
 
(1,535.4
)
 
(907.6
)
Asset impairments
(3,175.5
)
 
—

 
(31,170.1
)
 
—

(Loss) income from discontinued operations
$
152.1

 
$
108.6

 
$
(25,536.9
)
 
$
1,623.2